Clinical trial
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
NCT06020885 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- August 31, 2023
- Completion date
- October 30, 2025
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.